Wpływ substancji leczniczych na oś wątroba–jelito psów i kotów

PIŚMIENNICTWO

1. Anand S., Mande S.S.: Host-Microbiome Interactions: Gut-Liver Axis and Its Connection with Other Organs. npj Biofilms and Microbiomes, 2022, 8, 1, 1-10, doi:10.1038/s41522-022-00352-6.

2. Habermaass V., Olivero D., Gori E., Mariti C., Longhi E., Marchetti V.: Intestinal Microbiome in Dogs with Chronic Hepatobiliary Disease: Can We Talk about the Gut-Liver Axis? Animals (Basel), 2023, 13, doi:10.3390/ANI13203174.

3. Comito R., Porru E., Interino N., Conti M., Terragni R., Gotti R., Candela M., Simoni P., Roda A., Fiori J.: Metabolic Bile Acid Profile Impairments in Dogs Affected by Chronic Inflammatory Enteropathy. Metabolites, 2023, 13, doi:10.3390/METABO13090980/S1.

4. Schnabl B., Brenner D.A.: Interactions Between the Intestinal Microbiome and Liver Diseases. Gastroenterology, 2014, 146, 1513, doi:10.1053/J.GASTRO.2014.01.020.

5. Blake A.B., Guard B.C., Honneffer J.B., Lidbury J.A., Steiner J.M., Suchodolski J.S.: Altered Microbiota, Fecal Lactate, and Fecal Bile Acids in Dogs with Gastrointestinal Disease. PLoS One 2019, 14, doi:10.1371/JOURNAL.PONE.0224454.

6. Gogulski M., Ardois M., Grabska J., Libera K., Szumacher-Strabel M., Cieślak A., Strompfová V.: Dietary Supplements Containing Silymarin as a Supportive Factor in the Treatment of Canine Hepatopathies. Med Weter, 2020, 76, 700-708.

7. Mentula S., Harmoinen J., Heikkilä M., Westermarck E., Rautio M., Huovinen P., Könönen E.: Comparison between Cultured Small-Intestinal and Fecal Microbiotas in Beagle Dogs. Appl Environ Microbiol, 2005, 71, 4169, doi:10.1128/AEM.71.8.4169-4175.2005.

8. Ziese A.L., Suchodolski J.S.: Impact of Changes in Gastrointestinal Microbiota in Canine and Feline Digestive Diseases. Veterinary Clinics of North America: Small Animal Practice, 2021, 51, 155-169, doi:10.1016/J.CVSM.2020.09.004.

9. Honneffer J.B., Minamoto Y., Suchodolski J.S.: Microbiota Alterations in Acute and Chronic Gastrointestinal Inflammation of Cats and Dogs. World Journal of Gastroenterology: WJG 2014, 20, 16489, doi:10.3748/WJG.V20.I44.16489.

10. Chaitman J., Ziese A.L., Pilla R., Minamoto Y., Blake A.B., Guard B.C., Isaiah A., Lidbury J.A., Steiner J.M., Unterer S. i wsp.: Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole. Front Vet Sci, 2020, 7, 192, doi:10.3389/FVETS.2020.00192/FULL.

11. Suchodolski J.S.: Analysis of the Gut Microbiome in Dogs and Cats. Vet Clin Pathol, 2022, 50, 6-17, doi:10.1111/VCP.13031.

12. Suchodolski J.S., Markel M.E., Garcia-Mazcorro J.F., Unterer S., Heilmann R.M., Dowd S.E., Kachroo P., Ivanov I., Minamoto Y., Dillman E.M. i wsp.: The Fecal Microbiome in Dogs with Acute Diarrhea and Idiopathic Inflammatory Bowel Disease. PLoS One 2012, 7, doi:10.1371/JOURNAL.PONE.0051907.

13. Watson P.J., Roulois A.J.A., Scase T.J., Irvine R., Herrtage M.E.: Prevalence of Hepatic Lesions at Post-Mortem Examination in Dogs and Association with Pancreatitis. Journal of Small Animal Practice, 2010, 51, 566-572, doi:10.1111/J.1748-5827.2010.00996.X.

14. Siroka Z., Svobodova Z.: The Toxicity and Adverse Effects of Selected Drugs in Animals – Overview. Pol J Vet Sci, 2013, 16, 181-191, doi:10.2478/PJVS-2013-0027.

15. Hosack T., Damry D., Biswas S.: Drug-Induced Liver Injury: A Comprehensive Review. Therap Adv Gastroenterol, 2023, 16, doi:10.1177/17562848231163410.

16. Nelson K.: Paracetamol Toxicity in Dogs. Veterinary Record, 2019, 184, 594-594, doi:10.1136/VR.L2060.

17. Bello A.M., Dye C.: Current Perceptions and Use of Paracetamol in Dogs among Veterinary Surgeons Working in the United Kingdom. Vet Med Sci, 2023, 9, 679-686, doi:10.1002/VMS3.1058.

18. Trepanier L.A.: Idiosyncratic Drug Toxicity Affecting the Liver, Skin, and Bone Marrow in Dogs and Cats. Veterinary Clinics of North America: Small Animal Practice, 2013, 43, 1055-1066, doi:10.1016/J.CVSM.2013.04.003.

19. Trepanier L.A.: Idiosyncratic Toxicity Associated with Potentiated Sulfonamides in the Dog. J Vet Pharmacol Ther, 2004, 27, 129-138, doi:10.1111/J.1365-2885.2004.00576.X.

20. Licata A., Minissale M.G., Calvaruso V.: A Focus on Epidemiology of Drug-Induced Liver Injury: Analysis of a Prospective Cohort. Eur Rev Med Pharmacol Sci, 2017, 21, 112-121.

21. Schwartz M., Munana K.R., Olby N.J.: Possible Drug-Induced Hepatopathy in a Dog Receiving Zonisamide Monotherapy for Treatment of Cryptogenic Epilepsy. J Vet Med Sci, 2011, 73, 1505-1508, doi:10.1292/JVMS.11-0164.

22. Maria V.A.J., Victorino R.M.M.: Development and Validation of a Clinical Scale for the Diagnosis of Drug-Induced Hepatitis. Hepatology, 1997, 26, 664-669, doi:10.1002/hep.510260319.

23. Leise M.D., Poterucha J.J., Talwalkar J.A.: Drug-Induced Liver Injury. Mayo Clin Proc, 2014, 89, 95-106, doi:10.1016/j.mayocp.2013.09.016.

24. Richardson J.A.: Management of Acetaminophen and Ibuprofen Toxicoses in Dogs and Cats. Journal of Veterinary Emergency and Critical Care, 2000, 10, 285-291, doi:10.1111/J.1476-4431.2000.TB00013.X.

25. Luna S.P.L., Basílio A.C., Steagall P.V.M., Machado L.P., Moutinho F.Q., Takahira R.K., Brandao C.V.S.: Evaluation of Adverse Effects of Long-Term Oral Administration of Carprofen, Etodolac, Flunixin Meglumine, Ketoprofen, and Meloxicam in Dogs. Am J Vet Res, 2007, 68, 258-264, doi:10.2460/AJVR.68.3.258.

26. Hutchins R.G., Messenger K.M., Vaden S.L.: Suspected Carprofen Toxicosis Caused by Coprophagia in a Dog. J Am Vet Med Assoc, 2013, 243, 709-711, doi:10.2460/JAVMA.243.5.709.

27. Nakagawa K., Yamagami T., Takemura N.: Hepatocellular Toxicosis Associated with the Alternate Administration of Carprofen and Meloxicam in a Siberian Husky. J Vet Med Sci, 2005, 67, 1051-1053, doi:10.1292/JVMS.67.1051.

28. MacPhail C.M., Lappin M.R., Meyer D.J., Smith S.G., Webster C.R., Armstrong P.J.: Hepatocellular Toxicosis Associated with Administration of Carprofen in 21 Dogs. J Am Vet Med Assoc., 1998, 212, 1895-1901.

29. Raekallio M.R., Hielm-Björkman A.K., Kejonen J., Salonen H.M., Sankari S.M.: Evaluation of Adverse Effects of Long-Term Orally Administered Carprofen in Dogs. J Am Vet Med Assoc, 2006, 228, 876-880, doi:10.2460/JAVMA.228.6.876.

30. Kraus M.S., Thomason J.D., Fallaw T.L., Calvert C.A.: Toxicity in Doberman Pinchers with Ventricular Arrhythmias Treated with Amiodarone (1996-2005). J Vet Intern Med., 2009, 23, 1-6, doi:10.1111/j.1939-1676.2008.0227.x.

31. van Beusekom C.D., van den Heuvel J.J.M.W., Koenderink J.B., Russel F.G.M., Schrickx J.A.: Feline Hepatic Biotransformation of Diazepam: Differences between Cats and Dogs. Res Vet Sci, 2015, 103, 119-125, doi:10.1016/J.RVSC.2015.09.016.

32. Costa R.S., Jaffey J.A., Evans J.: Flumazenil Treatment for Diazepam-Associated Neurological Signs in a Cat With a Portosystemic Shunt. Top Companion Anim Med., 2023, 56-57, doi:10.1016/J.TCAM.2023.100806.

33. Macho L.P., Center S.A., Randolph J.F., Dumars L.A., Rush S.E., Kate Cameron M., Lucy J.M., Hall-Fonte D.L., McDonough S.P., Peters-Kennedy J. i wsp.: Clinical, Clinicopathologic, and Hepatic Histopathologic Features Associated with Probable Ketoconazole-Induced Liver Injury in Dogs: 15 Cases (2015-2018). J Am Vet Med Assoc, 2020, 256, 1245-1256, doi:10.2460/JAVMA.256.11.1245.

34. Heading K., Brockley L., Bennett P.: CCNU (Lomustine) Toxicity in Dogs: A Retrospective Study (2002-07). Aust Vet J, 2011, 89, 109-116, doi:10.1111/J.1751-0813.2011.00690.X.

35. Dedeaux A.M., Flesner B.K., Reinhart J.M., Langohr I.M., Husnik R., Geraci S.N., Taboada J., Rademacher N., Thombs L.A., Bryan J.N. i wsp.: Biochemical, Functional, and Histopathologic Characterization of Lomustine-Induced Liver Injury in Dogs. Am J Vet Res, 2020, 81, 810-820, doi:10.2460/AJVR.81.10.810.

36. Wallisch K., Trepanier L.A.: Incidence, Timing, and Risk Factors of Azathioprine Hepatotoxicosis in Dogs. J Vet Intern Med., 2015, 29, 513, doi:10.1111/JVIM.12543.

37. Webb C.B., Twedt D.C.: Acute Hepatopathy Associated with Mitotane Administration in a Dog. J Am Anim Hosp Assoc, 2006, 42, 298-301, doi:10.5326/0420298.

38. Zhao Q., Chen Y., Huang W., Zhou H., Zhang W.: Drug-Microbiota Interactions: An Emerging Priority for Precision Medicine. Signal Transduct Target Ther, 2023, 8, doi:10.1038/S41392-023-01619-W.

39. Battle A., Lane A., Parish H., Rushing S., Johnson J.L., Weldon A.J.: Interactions Between the Gut Microbiota and Common Cardiovascular Drugs. US Pharm., 2023, 48, 18-21.

40. Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L.: Mapping Human Microbiome Drug Metabolism by Gut Bacteria and Their Genes. Nature, 2019, 570, 462, doi:10.1038/S41586-019-1291-3.

41. Pilla R., Gaschen F.P., Barr J.W., Olson E., Honneffer J., Guard B.C., Blake A.B., Villanueva D., Khattab M.R., AlShawaqfeh M.K. i wsp.: Effects of Metronidazole on the Fecal Microbiome and Metabolome in Healthy Dogs. J Vet Intern Med., 2020, 34, 1853-1866, doi:10.1111/JVIM.15871.

42. Stavroulaki E.M., Suchodolski J.S., Pilla R., Fosgate G.T., Sung C.H., Lidbury J.A., Steiner J.M., Xenoulis P.G.: Short- and Long-Term Effects of Amoxicillin/Clavulanic Acid or Doxycycline on the Gastrointestinal Microbiome of Growing Cats. PLoS One 2021, 16, e0253031, doi:10.1371/JOURNAL.PONE.0253031.

43. Maier L., Pruteanu M., Kuhn M., Zeller G., Telzerow A., Anderson E.E., Brochado A.R., Fernandez K.C., Dose H., Mori H. i wsp.: Extensive Impact of Non-Antibiotic Drugs on Human Gut Bacteria. Nature, 2018, 555, 623-628, doi:10.1038/NATURE25979.

44. Oh B., Boyle F., Pavlakis N., Clarke S., Guminski A., Eade T., Lamoury G., Carroll S., Morgia M., Kneebone A. i wsp.: Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Front Oncol, 2021, 11, doi:10.3389/FONC.2021.706331.

45. Costa M., Weese J.S.: Methods and Basic Concepts for Microbiota Assessment. Vet J, 2019, 249, 10-15, doi:10.1016/J.TVJL.2019.05.005.

46. Jergens A.E., Heilmann R.M.: Canine Chronic Enteropathy – Current State-of-the-Art and Emerging Concepts. Front Vet Sci, 2022, 9, doi:10.3389/FVETS.2022.923013.

47. Perondi F., Bisanzio D., Adami R., Lippi I., Meineri G., Cutrignelli M.I., Massa S., Martello E.: The Effect of a Diet Supplement Containing S-Acetyl-Glutathione (SAG) and Other Antioxidant Natural Ingredients on Glutathione Peroxidase in Healthy Dogs: A Pilot Study. Ital J Anim Sci, 2023, 22, 589-593, doi:10.1080/1828051X.2023.2221073.

48. Martello E., Perondi F., Bisanzio D., Lippi I., Meineri G., Gabriele V.: Antioxidant Effect of a Dietary Supplement Containing Fermentative S-Acetyl-Glutathione and Silybin in Dogs with Liver Disease. Vet Sci, 2023, 10, doi:10.3390/VETSCI10020131/S1.

49. Marchegiani A., Fruganti A., Gavazza A., Mangiaterra S., Candellone A., Fusi E., Rossi G., Cerquetella M.: Evidences on Molecules Most Frequently Included in Canine and Feline Complementary Feed to Support Liver Function. Vet Med Int, 2020, doi:10.1155/2020/9185759.

50. Loguercio C., Festi D.: Silybin and the Liver: From Basic Research to Clinical Practice. World J Gastroenterol, 2011, 17, 2288-2301, doi:10.3748/WJG.V17.I18.2288.

51. Morishima C., Shuhart M.C., Wang C.C., Paschal D.M., Apodaca M.C., Liu Y., Sloan D.D., Graf T.N., Oberlies N.H., Lee D.Y.W. i wsp.: Silymarin Inhibits in Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection. Gastroenterology 2010, 138, doi:10.1053/J.GASTRO.2009.09.021.

52. Yanyu X., Yunmei S., Zhipeng C., Qineng P.: The Preparation of Silybin-Phospholipid Complex and the Study on Its Pharmacokinetics in Rats. Int J Pharm, 2006, 307, 77-82, doi:10.1016/J.IJPHARM.2005.10.001.

53. Kidd P.M.: Bioavailability and Activity of Phytosome Complexes from Botanical Polyphenols: The Silymarin, Curcumin, Green Tea, and Grape Seed Extracts. Alternative Medicine Review, 2009, 14, 226-246.

54. Sgorlon S., Stefanon B., Sandri M., Colitti M.: Nutrigenomic Activity of Plant Derived Compounds in Health and Disease: Results of a Dietary Intervention Study in Dog. Res Vet Sci, 2016, 109, 142-148, doi:10.1016/J.RVSC.2016.10.005.

55. Sozen H., Celik O.I., Cetin E.S., Yilmaz N., Aksozek A., Topal Y., Cigerci I.H., Beydilli H.: Evaluation of the Protective Effect of Silibinin in Rats with Liver Damage Caused by Itraconazole. Cell Biochem Biophys, 2015, 71, 1215–1223, doi:10.1007/S12013-014-0331-8.

56. Avizeh R., Najafzadeh H., Jalali M.R., Shirali S.: Evaluation of Prophylactic and Therapeutic Effects of Silymarin and N-Acetylcysteine in Acetaminophen-Induced Hepatotoxicity in Cats. J Vet Pharmacol Ther, 2010, 33, 95-99, doi:10.1111/J.1365-2885.2009.01100.X.

57. Collado M.C., Meriluoto J., Salminen S.: Adhesion and Aggregation Properties of Probiotic and Pathogen Strains. European Food Research and Technology, 2008, 226, 1065-1073, doi:10.1007/S00217-007-0632-X/FIGURES/2.

58. Schmitz S., Suchodolski J.: Understanding the Canine Intestinal Microbiota and Its Modification by Pro-, Pre- and Synbiotics – What Is the Evidence? Vet Med Sci, 2016, 2, 71-94, doi:10.1002/VMS3.17.

59. Xu H., Huang W., Hou Q., Kwok L.Y., Laga W., Wang Y., Ma H., Sun Z., Zhang H.: Oral Administration of Compound Probiotics Improved Canine Feed Intake, Weight Gain, Immunity and Intestinal Microbiota. Front Immunol, 2019, 10, doi:10.3389/FIMMU.2019.00666.

60. D’Angelo S., Fracassi F., Bresciani F., Galuppi R., Diana A., Linta N., Bettini G., Morini M., Pietra M.: Effect of Saccharomyces Boulardii in Dogs with Chronic Enteropathies: Double-Blinded, Placebo-Controlled Study. Veterinary Record, 2018, 182, 258-258, doi:10.1136/VR.104241.

61. Molina R.A., Villar M.D.U., Miranda M.H., Maldonado N.C., Vignolo G.M., Nader-Macias M.E.F.: A Multi-Strain Probiotic Promoted Recovery of Puppies from Gastroenteritis in a Randomized, Double-Blind, Placebo-Controlled Study. The Canadian Veterinary Journal 2023, 64, 666.

62. Aktas M.S., Borku M.K., Ozkanlar Y.: Efficacy of Saccharomyces Boulardii as a Probiotic in Dogs with Lincomycin Induced Diarrhoea. Bulletin of the Veterinary Institute in Puławy, 2007, 51.